 PARIS and CAMBRIDGE, Mass., March 19, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the Company, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces that, on March 16, 2021, the Paris Commercial Court rendered a judgement in the proceedings on the merits opposing the Company to Negma Group Ltd Negma related to the ORNANEBSA agreement entered into on August 21 2019. 